risk of disease exacerbations. Implications for Practice: Not all women respond similarly to a routine surveillance visit; thus, providers must determine who may be at increased risk of emotional distress and physiologic alteration. Survivor-provider communication facilitates immediate resolution of concerns. Explanations of symptom meaning reduce anxiety and uncertainty and by extension may help resolve immune alteration. Between visits, this could be done by nurse-operated telephone-based ''help lines.'' C urrently, it is estimated that 3.1 million breast cancer survivors live in the United States, and 90% of women with a diagnosis of localized breast cancer are expected to survive 5 years or longer. 1 The steady decline in mortality due to breast cancer has resulted in more women living with and managing the acute and late-emerging adverse effects of treatment. Furthermore, breast cancer is often a disease of older women who manage additional chronic conditions. Eighty percent of breast cancer is diagnosed in women older than 50 years, with the median age at diagnosis of 61 years. 1 Overall, and in response to the increasing number of cancer survivors, increased understanding of cancer survivorship has been a research priority of the National Cancer Institute's Office of Cancer Survivorship as evidenced by professional conferences focusing on survivorship (American Cancer Society, the National Cancer Institute's Office of Cancer Survivorship, the Livestrong Foundation, the American Society for Clinical Oncology, and the Centers for Disease Control and Prevention) as well as calls to action to address the unique concerns (eg, lower quality of life, late-emerging adverse effects of treatment that impact health) faced by survivors. 2 Across disciplines there is substantial recognition of the complex healthcare issues, physical and emotional, related to a previous cancer diagnosis coupled with additional comorbid conditions and the associated ongoing planning, surveillance, and intervention requirements during cancer survivorship.
n Background
Given that women interact with multiple healthcare providers and often have multiple comorbid conditions, providing optimal cancer survivorship care is a complex endeavor that must integrate emotional, physiologic, and communication components. Uncertainty theory suggests that when these components are integrated successfully a new view of life is created, based on opportunity and hope rather than anxiety and uncertainty. 3, 4 The Reservoir Model also explains how stressful events accumulate (''add up'') over time but can be resolved using stressreducing mechanisms. 5 Overall, little is known about how naturally occurring stressful events such as regularly scheduled medical oncology appointments (as opposed to laboratory-induced stressors of public speaking or solving mathematical problems) are associated with immune responses for breast cancer survivors. Even less is known about the association of survivor-provider communication processes with emotional and physiologic responses among breast cancer survivors. Therefore, the purpose of this pilot study was to evaluate associations between emotional well-being (concerns about cancer recurrence, changes in uncertainty and anxiety), physiologic well-being (fluctuations in cytokine levels, lymphocyte counts), and survivor-provider communication processes (women's plans for their visit, the ability to negotiate decision-making roles) immediately before and the morning after a regularly scheduled medical oncology surveillance visit. A conceptual framework integrating these concepts guided this study (Figure) .
Emotional Well-being During Breast Cancer Survivorship
Although 5-year survival is still considered a major milestone for recovery, most breast cancer survivors attend routine medical follow-up visits throughout survivorship and remain anxious and nervous about these visits. 6Y10 Breast cancer survivors emphasize intermittent-episodic anxiety and uncertainty about the potential for cancer recurrence occurring before medical visits. 8, 9 Women report ''waiting'' for the next office visit, the next medical test, and the next visit with their provider 8 in an ongoing state of uncertainty and ''needing to know'' if their cancer has returned. 9 The conceptualization of how survivors experience the threat of cancer recurrence continues to evolve, moving from a single dimension of fear to multidimensional emotional, cognitive, and behavioral reactions including individual appraisal of the chance of cancer recurrence. 11Y13 Other factors, such as younger age, ethnicity/race, marital status, and education, have been associated with fear of recurrence, but psychosocial factors, such as cognitions, beliefs, and emotions, are more strongly associated with the fear of another future cancer diagnosis.
14 Anxiety and uncertainty about the potential for cancer recurrence can be triggered by events such as media coverage and medical office visits. 9, 14 Psychosocial factors (such as uncertainty, distress, and intrusive cognitions) vary, depending on personal events and disease progression, 9 yet a significant amount of evidence reinforces the prevalence and stability of the existence of fear of cancer recurrence over time regardless of the actual risk of recurrence. 13, 15, 16 An extensive review of the concept of fear of recurrence by Koch et al 14 evaluated 15 samples of cancer survivors ranging in size from 94 to 1366 participants, finding that the amount of fear of cancer recurrence remained stable over time. Koch et al 14 reported that self-reported fear of recurrence is highly prevalent and endures well past initial treatment, with most survivors experiencing low to moderate amounts of fear of recurrence. Time since diagnosis is also not usually associated with fear of recurrence. 15 In a systematic review of 21 studies, only 1 author reported a significant association between time since diagnosis and the fear of cancer recurrence. 15, 17 In addition, in a longitudinal study of cancer survivors, Ghazali et al 18 found 30% of cancer survivors reported significant levels of fear of cancer recurrence that did not fluctuate over time. These findings indicate that concerns about, and the corresponding fear of, cancer recurrence is prevalent and unchanging among short-and long-term cancer survivors.
Physiologic Well-being During Breast Cancer Survivorship
Complicating provider overall assessment of a cancer survivor's well-being, studies have found that subjective reports of emotional well-being do not always correlate with objective measures of physiologic well-being. 19, 20 Studies show that patients can adopt a pleasant affect toward medical providers yet remain highly anxious; thus, providers may not always be aware of emotional distress and the associated potential physiologic responses to distress. 20 Studies of physiologic responses to stressors have often been conducted in vitro, identifying cellular pathways and responses, but not addressing external processes such as patient worry and patient-provider communication that may impact responses to an identified stressor. 21 Physiologic responses to real-world stressors such as an upcoming medical oncology visit are less well understood than emotional responses. Previous research links stressful events to altered immunity in both animal models 22 and cardiac patients. 23 Other research indicates that emotional stress is associated with decreased natural killer (NK) cell activity and decreased T helper 1 (T H 1) cytokines interleukin 2 (IL-2) and interferon + (IFN-+) among daughters of women with breast cancer. 24 One of the most robust findings of immune response to acute stress is an increase in the number of circulating NK cells associated with stressful events. 25 Yet among women who completed treatment for breast cancer, research demonstrates a lesser increase in the number of NK cells after an acutely stressful event as compared with a matched control group of women without a previous diagnosis of breast cancer, indicating complexity and variability in stress responses. 26 Breast cancer survivors also demonstrated a slower return to NK baseline levels as compared with healthy age-matched women in the control group. 26 Altered immunity and associated emotional stressors may impact cancer development, as well as short-term (minor viral illnesses) and long-term (exacerbation of existing illness) health. This is due to the suppression of innate immunity during acute stress, suppressing T H 1-mediated responses (decreases in T H 1 cytokines such as IFN-+ and IL-2, reduced IL-2 receptor expression, and decreases in the normal T-cytotoxic and NK absolute counts and activity) that protect against infections and some tumors and the increased T H 2 responses (increases in T H 2 cytokines such as IL-4 and IL-5) that may exacerbate comorbid conditions frequently associated with older age (eg, cardiovascular disease, osteoporosis, rheumatoid arthritis, diabetes).
27Y29
Because breast cancer survivors consider follow-up medical office visits as stressful ''high-stakes'' events, physiologic responses (eg, altered cytokine levels and lymphocyte counts) can be seen in addition to emotional responses such as anxiety and uncertainty about cancer recurrence. 25, 30, 31 Elevated baseline cortisol levels and blunted cortisol reactivity to the acute stress of routine mammograms in long-term breast cancer survivors have also been reported. 32 Furthermore, an individualized perception of stress (including the presence of intrusive thoughts) and prolonged exposure to a stressor have been linked to reduced circulating lymphocyte counts and activity. 19, 25, 33 Older persons and persons with comorbid diseases have immune systems that are less robust than younger persons, making them vulnerable to the short-and long-term adverse effects of altered immunity (eg, minor illness and worsening autoimmune diseases such as arthritis). 25 Survivors are also living longer; thus, evaluating the effect of altered immunity on short-and long-term health becomes important. However, because immunological responses are individualized and influenced by multiple health-and disease-related factors, interpretation across studies remains difficult.
Communication With Providers
The importance of communication was noted by Hippocrates who wrote, ''I will remember that there is art to medicine as well as science and that warmth, sympathy, and understanding may outweigh the surgeon's knife or the chemist's drug.'' 34 Patientprovider communication has been previously associated with both emotional well-being of cancer survivors 7 and altered immunity (increased cortisol). 35 Communication with healthcare providers has been shown to reduce uncertainty and distress for breast cancer survivors and as such can be considered a stress-reducing mechanism. 7 Theoretically, a healthcare provider offers information to patients from the position of expert or authority. 3, 7, 36, 37 When the information is delivered in a believable way, uncertainty and associated anxiety are reduced. 4 When the conversation is perceived by survivors to be more patient centered, anxiety and uncertainty are also reduced. 6, 38 As an example, during routine breast examinations associated with surveillance-focused medical oncology office visits, women may be anxious about whether the doctor ''found a new lump,'' knowing that an abnormal clinical breast examination is known to be a strong indicator of cancer recurrence. 39 Women may also worry about whether existing symptoms, such as pain or fatigue, indicate cancer recurrence. Survivor-provider communication offers immediate interpretation and explanations of existing symptoms. Between visits, phone calls to nurses or other trusted providers can provide immediate interpretation of the meaning of symptoms (eg, whether the symptom indicative of recurrence or another illness). Thus, communication with providers plays a major role in reducing anxiety and uncertainty by the provision of information and reassurance about the meaning of symptoms. 7 In addition, the ability of patients to present experienced symptoms and concerns that are worrisome and have them fully addressed by providers (a patient-centered approach) can potentially reduce uncertainty and anxiety about the meaning of experienced symptoms with respect to cancer recurrence, enhancing emotional well-being. 6 
THE SURVIVOR-PROVIDER RELATIONSHIP
The survivor-provider relationship is influential, given the longstanding nature of ongoing breast cancer surveillance throughout survivorship. Often there is an established patient-provider relationship, and women are able to present their questions and concerns to providers, receiving information and explanation. However, this is not a universal experience. Most women form a plan for their visit, developing specific questions and issues they wish to discuss with providers then present these symptoms and concerns with varying degrees of success. 6, 40, 41 COMMUNICATION PROBLEMS Communication problems also exist. Providers can address symptoms, anxiety, and uncertainty of breast cancer survivors only if they are aware of these issues. Women must be willing to communicate their concerns to providers, and providers must be willing to address those concerns. However, not all breast cancer survivors share information during office visits. For example, women report enduring worrisome symptoms such as fatigue that they have not discussed with providers. 6 Negotiating decision-making roles is another area that may result in less than optimal communication. Whereas most breast cancer survivors are able to negotiate the decision-making role they desire (active, passive, or collaborative), some are unable to do so. 6, 7 Previous research has shown that as many as 52% of women adopt a more passive or active decision-making role with providers than they initially desired. 7 Taken together, previous research demonstrates that women living with breast cancer have multiple ongoing comorbid illnesses, manage late-emerging adverse effects of initial treatment, and engage in lengthy ongoing surveillance for cancer recurrence. The degree to which women are concerned about the potential for cancer recurrence is prevalent and individualized. Increased anxiety and uncertainty about cancer recurrence can be triggered by immediate events such as a routine surveillance visit. The acute anxiety and uncertainty are theoretically amenable to change, in part due to the credible presentation of information by a trusted healthcare provider. Emotional responses may in turn impact physiologic responses to the stress of a routine surveillance visit, impacting overall well-being during breast cancer survivorship ( Figure) .
n Methods
Procedures
After obtaining institutional review board approval, recurrencefree breast cancer survivors 2 or more years beyond completion of original treatment were identified using appointment schedules, then telephoned by medical oncology office staff to introduce the study. If women were willing to learn more about the study, names were given to the principal investigator who called and explained the study in greater detail and obtained verbal consent. On the day of their appointment, women were asked to arrive 30 minutes early. Women were met in the medical oncology office, written consent was obtained, and selfreport measures were administered by a trained research assistant. Immediately prior to the visit, measures of immunity were obtained in conjunction with regular blood work. The following morning, postvisit immune measures were collected by a trained phlebotomist research assistant in the woman's home, as was postvisit self-report data. Collecting blood specimens within a standardized 3-hour time (9 AM to noon) controlled for diurnal variation. Blood specimens were delivered to the testing laboratory, and surveys were placed in an envelope, sealed, and returned directly to the principal investigator.
Sample and Setting
Twenty-seven community-dwelling breast cancer survivors were recruited. All were white. Inclusion criteria were as follows: (a) cognitively intact women 40 years or older (because younger women of childbearing age often have different issues and concerns such as fertility related to treatment, as well as more aggressive disease and less age-associated comorbid conditions that may be associated with immunity); (b) a previous diagnosis of breast cancer stage 1 or greater; (c) no history of cancer recurrence; (d) minimum 2 years after treatment; and (e) adequate veins for venipuncture. Two years posttreatment allowed initial acute adverse effects to abate and chronic symptoms to emerge that could create concerns about the potential for cancer recurrence. Self-reported vein adequacy excluded women who might attach undue stress to the postvisit venipuncture confounding results. Women taking prescription anti-inflammatory medications were also excluded. Women were given a $20 gift card to a local supermarket in appreciation for participation. No women experienced a cancer recurrence during these visits. Table 1 presents a summary of instrument internal consistency and descriptive results for self-reported data.
Measures
Current health status. Current health status within the past month was measured previsit with a 27-item questionnaire addressing existing chronic comorbid conditions and recent minor illnesses (eg, a minor upper respiratory illness).
Symptoms. The Symptom Distress Scale 42 was used previsit to determine the number of experienced symptoms and associated bother, as well as the ability to manage symptoms within the previous month, using a 5-point Likert-type scale (1 = slight to 5 = very severe). Symptoms theoretically represent triggers about cancer recurrence if women do not understand the meaning or cause of experienced symptoms. 3 Scores are summed with higher scores indicating greater incidence and more bother. Validity in cancer patients has been demonstrated by a positive correlation with the Profile of Mood States. 43 
Emotional Responses
Concern about cancer recurrence. The nature and extent of women's fears about breast cancer recurrence were measured previsit using the Concerns About Recurrence Scale (CARS). 12 The 2-part survey uses a 5-point Likert-type scale ranging from 0 (not at all) to 4 (extremely) response format indicating the extent of worry related to each item; 4 items focus on time spent thinking about recurrence, frequency of thoughts, and intensity of fear about recurrence followed by 26 items assessing the nature of women's fear of recurrence. This instrument measures a trait-like attribute reflecting concerns about the potential for cancer recurrence, as opposed to more immediate responses of uncertainty or anxiety triggered by a particular stressor. Developmental and psychometric evaluation of the CARS demonstrated no evidence that cancer stage, time since diagnosis, or type of surgery influenced fear of breast cancer recurrence. 12 Higher summed scores indicate greater ongoing concern about future recurrence. Convergent validity of the CARS was previously demonstrated in breast cancer survivors using the intrusive thoughts (r = 0.64, P G .001) and avoidance (r = 0.50, P G .001) subscales of the Impact of Events Scale 44 and the distress (r = 0.54, P G .001) and well-being (r = j0.44, P G .001) subscales of the Mental Health Inventory. 45 Uncertainty. Survivor uncertainty was measured before and after the medical oncology visit using the 22-item Uncertainty in Illness ScaleYSurvivor version. 46 Respondents indicate their level of agreement on a 5-point Likert-type scale ranging from strongly agree to strongly disagree. Scores are summed with higher scores reflecting greater uncertainty. Validity in cancer patients has been demonstrated by positive associations with emotional distress, fears of recurrence, and symptom bother. Anxiety. The State-Trait Anxiety Inventory 47 was used to measure transient anxiety (state, 20 items) before and after the medical oncology visit. Respondents indicate their agreement with items measuring feelings of apprehension, tension, nervousness, comfort, and decision making. Scores are summed with higher scores indicating more anxiety. We also included a single item specifically asking about anxiety related to the upcoming medical visit.
Immune Responses
Cytokine levels and lymphocyte counts were obtained previsit and postvisit to assess immune status. Selected cytokines and lymphocytes (cytokines IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-+, tumor necrosis factor !, CD40 ligand, and IL-2 receptor) were part of a bundled assay, which was less expensive to perform versus individual assays, measured using a multianalytic fluorescent detection method in contrast to the more familiar enzyme-linked immunosorbent assays (ELISA). 48 This procedure allows the simultaneous detection of multiple serum cytokines as opposed to ELISA assays that detect 1 cytokine per 
Patient-Provider Communication
Visit plan. Data were obtained previsit about a woman's plan for her upcoming medical visit. Open-ended items were as follows: ''How do you plan to use the time you spend with your provider today?'' and ''Is there anything you plan to (or want to) discuss with your provider today?'' Women wrote their responses in the data collection booklet. These data were used to create a 3-level variable labeled ''plan specificity,'' with lower scores representing a more specific plan for the upcoming visit. Two investigators evaluated responses using a directed content analysis, discussing all responses until agreement was reached.
Responses were assigned a numeric value indicating plan specificity. A value of 1 represented a highly specific plan such as clearly defined specific questions, or clearly defined goals such as discussing identified symptoms or obtaining a referral. A value of 2 indicated a visit plan existed but lacked specificity, for example, ''make sure I'm alright'' or ''get results of my blood tests.'' A value of 3 indicated no plan at all; women answered ''no'' to having a plan for discussing a topic with their provider or wrote ''no plan'' for how they planned to use their visit time.
Decision-making role. The Control Preferences Scale 49 was used to determine the women's desired healthcare decisionmaking role compared with how healthcare decisions were actually made during their medical surveillance visit. Decisionmaking role statements are presented on a 1-to-5 continuum, with higher scores indicating more active decision making. Women select the one statement that most closely describes their desired decision-making role before the medical visit, then after the medical appointment select the one statement that most closely described how decisions were actually made (attained decision-making role). Items include the following: ''I prefer to leave all decisions regarding my treatment to my doctor, physician assistant, or nurse practitioner'' (score = 1, most passive) and ''I prefer to make the final selection about which treatment I will receive'' (score = 5, most active). We subtracted desired decisionmaking role score from attained decision-making role score to determine a discrepancy score. 7 The discrepancy score reflects both the magnitude and direction of the incongruity between the respondent's desired and attained role. Negative scores can be interpreted as a woman desiring a more active role than she attained during her visit. Positive scores indicate that a woman desired a more passive decision-making role than she attained. A score of 0 indicates no difference between attained and desired decision-making role. Previous research supports the ability to choose decision-making role preferences on a continuum among breast cancer survivors 7, 50 and among colorectal cancer patients. 51 
Analysis
Descriptive demographic and personal information was calculated using means (SD or range) for numeric variables, and percentages by category for nominal variables. For response variables, we present descriptive information using the mean (SD). We treated response variables as continuous, taking the square root or log transformation if needed to improve normality. Pearson product coefficients were used to report correlations between continuous variables. To examine which variables demonstrated change over time between previsit and postvisit data collection, correlated-samples t tests were used. Finally, to explore the degree to which other variables account for previsit-postvisit change in a biomarker, we use a conditional change approach, estimating the regression of a postvisit biomarker on both the previsit value of the biomarker and a previsit self-report measure. The coefficient of the previsit self-report measure is then the predictive value of self-report, adjusted for the baseline biomarker. Conceptually, this is the expected change in the standardized postvisit biomarker that would be produced by a 1-SD change in the self-report measure, within levels of the previsit biomarker. Because of the smaller nature of this sample, we report unbiased continuous P values, allowing the readers their own interpretation of results.
n Results
Data were analyzed using IBM SPSS Statistics version 22 (IBM Corp, Armonk, NY). Study booklets were checked prior to a woman leaving the medical office and for postvisit data prior to the research assistant leaving a woman's home; thus, there were minimal missing data in this study. Missing values for self-reported measures were replaced with the item mean. No missing physiologic data were replaced (1 postvisit sample was not suitable for testing). Participant ages ranged from 43 to 81 years (mean, 60.5 years). Most women were married, and the vast majority had education beyond high school. One-third of women reported a minor illness within the last month (Table 2 ). Women reported on average 4 comorbid conditions and endorsed 5 symptoms experienced in the previous month related to previous cancer treatment. The most frequently endorsed comorbid conditions were hypertension, anxiety, and arthritis. The most frequently endorsed treatment-related adverse effects were fatigue, underarm tenderness or numbness, and weight gain. Trouble thinking was reported by 41% of women. The most bothersome (and difficult to manage) treatment-related symptoms were weight gain, trouble thinking, and arm weakness and mobility issues. Concerns about overall cancer recurrence were moderate (mean, 46 [SD, 26.5] ; range, 4Y102; Table 1 ).
Emotional Response
We operationalized a stressor as a regularly occurring medical oncology surveillance visit, potentially precipitating uncertainty and anxiety as well as immune alteration. Findings showed that there was a strong correlation between overall concern about cancer recurrence and a single item asking about the extent of self-reported anxiety about the upcoming medical visit (r = 0.68, P = .00).
To examine which variables demonstrated change between previsit and postvisit data collection, correlated-samples t tests were used. Findings showed that breast cancer survivors reported decreased uncertainty (t 26 = 19.98, P = .000) and state anxiety (t 26 = 21.28, P = .000) postvisit.
Physiologic Responses
Natural killer cells increased in 70% of women after visit (t 24 = j2.11, P = .045), suggesting previous immune alteration had occurred (decreased innate immunity prior to the visit). In addition, one-third of women reported a minor illness in the month prior to their visit, although the association of anxiety and minor illness was not directly addressed and should be considered suggestive rather than evidence of an association between physical and emotional events. It should be noted that data were not collected during flu season when viral illness incidence is high. Other immune markers showed inconsistent change before and after the medical oncology surveillance visit.
Patient-Provider Communication

THE SURVIVOR-PROVIDER RELATIONSHIP
On average, women had been interacting with the same provider for 4.2 years, implying an established relationship (range, 2Y15 years; Table 2 ). When asked how they planned to spend time with their provider during their medical oncology visit, 70% indicated they had something very specific to discuss with providers at their visit such as symptoms, stopping medications, questions about genetic testing, or breast reconstruction. Another 11% had a moderately specific plan such as obtaining the results of laboratory tests or discussing their overall health. The remaining women did not have a plan for their visit.
Not all women were able to attain their preferred decisionmaking role with their provider, indicating communication problems. Calculating the difference between preferred and attained role (with 0 indicating no difference) demonstrated that 66% were able to successfully negotiate their desired role. One-third of women reported that during the visit they were more active or more passive than they originally desired (Table 3) .
Emotional, Physiologic, and Communication Associations
To explore whether change in emotional responses predicted change in immunity before and after a medical oncology office visit, we initially used log transformations for ease in interpreting standardized coefficients of change in previsit-postvisit immunity. This allowed us to assess the interconnectedness of emotional and physiologic responses to a stressful event. Using a conditional change approach estimating change in postvisit values conditional on previsit values, our findings consistently demonstrated that greater overall concerns about cancer recurrence were highly associated with increased change in levels of interleukins after visit, indicating that those with more overall concerns experienced greater immune alteration (Table 4) . Associations were also found between changes in previsit-postvisit state anxiety and 3 proinflammatory cytokines: CD40L, tumor necrosis factor !, and IL-2r (IL-2r can be both proinflammatory and anti-inflammatory, ultimately impacting T-cell responses) and for CD19 cell counts (that activate B cells eliciting antibody production). Changes in uncertainty and state anxiety predicted changes in CD40L. Although findings showed that the number of absolute NK cells rose after visit, self-reported measures of anxiety and uncertainty were not associated with this increase in NK cells, consistent with literature demonstrating that subjective and objective measures of well-being are not necessarily associated. In summary, immediate emotional responses (uncertainty, anxiety) to an upcoming medical oncology were associated with change in immune status before and after visit, as was the more global concern about cancer recurrence.
To explore whether communication processes (measured by a woman's plan for her visit and her ability to successfully negotiate her desired decision-making role with her provider) predicted change in physiologic and emotional outcomes, we used regression analyses (F 22 = 3.23, P = .06). Closer examination of the coefficients showed that while a more specific and welldefined visit plan predicted greater change in previsit-postvisit uncertainty (theoretically indicating that women with more specific concerns were able to attribute meaning to their concerns and symptoms at the end of the visit; standardized B= j0.506, P = .02) the ability to successfully negotiate decision-making roles did not predict previsit-postvisit change in uncertainty. Furthermore, neither visit plan specificity nor the ability to successfully negotiate desired decision-making roles predicted previsit-postvisit change in anxiety, suggesting that the process of patient-provider communication was less influential than communication about visit outcomes (no recurrence detected) with respect to anxiety. Visit plan specificity and negotiation of decision-making roles did not predict change in immune status.
n Discussion and Conclusion Overall, our findings support the association of emotional aspects of ongoing cancer surveillance with physiologic responses to regularly scheduled medical oncology surveillance visits. Consistent with findings of Koch et al, 14 women reported an overall moderate level of concerns about cancer recurrence (Table 1. ). There was an association between general concerns about cancer recurrence and immune alterations, namely, for interleukins and cytokines. However, change in the direction of immune alteration was inconsistent. Some women had increasing values of proinflammatory interleukins and increasing numbers of lymphocytes, whereas others showed decreasing or no change in levels of lymphocytes and/or interleukins, suggesting that responses to an upcoming medical office visit are individualized and complex. Manifestations of individual response are seen in the association of anxiety and uncertainty with immunity (Table 4 .) One explanation may be that for some women an increase in proinflammatory markers postvisit indicates that the visit is a reminder of their previous cancer diagnosis (eg, rumination, prolonging immune alteration), despite receiving good news that no recurrence was detected. This could result in a delay of resolution.
Regardless of the mechanisms and possible explanations for differences in the timing of resolution, alterations in immunity have the potential to predispose women to exacerbations of existing comorbid illnesses, as well as place women at risk of additional minor illnesses such as an upper respiratory tract infection related to a T H 1-to-T H 2 shift from innate to adaptive immunity. Because not all women respond in a similar fashion to an upcoming medical oncology surveillance visit, there is a need to determine who may be most at risk of more acute alterations in immunity related to the episodic anxiety and uncertainty that is inherent in ongoing surveillance for recurrence after treatment completion.
The most consistent physiologic change in this study was an increase postvisit in NK cell counts; however, only 70% of women experienced this increase. The increase in NK cells implies a stress response (T H 1 suppression) presumably to the upcoming office visit (and the associated anxiety related to the overall purpose of a surveillance visit, assessing for cancer recurrence), although it is possible that other life stressors contributed to this alteration. It is unknown when the increase in NK cells began, given that blood samples were obtained the morning after the medical oncology visit, although resolution can begin within an hour of resolving a stressor. 52 Previous research about the timing of NK alteration is mixed; some studies focus on the prestress period with a corresponding decrease in NK cell counts; others demonstrate increases in poststress NK cell counts, and still other studies of stressors such as public speaking report transient increases in NK cell counts but do not clearly define when the increases and/or decreases occurred. 25, 52 Stressful event response variability in NK cell counts during a naturalistic stressful event (tandem skydiving) found by Breen et al 52 demonstrates increases in NK cell counts both immediately before boarding and immediately after landing, illustrating the ongoing complexity and challenge of ascertaining the relationship between stressful events and physiologic responses. Additional researchers discuss NK cell activity as opposed to NK cell counts finding decreased activity without corresponding fluctuation in cell counts, and others investigate the individual appraisal of stress in relation to alterations in immunity with inconsistent findings. 25 
Limitations
The ability to detect significant change in immune markers is dependent on sample size and thus restricted by the exploratory nature of this study, rendering these findings from a smaller sample worthy of enhanced future exploration. Furthermore, given the previsit-postvisit nature of our data collection, we do not know a woman's usual baseline for physiologic and emotional measures, nor can we determine when these women began to experience emotional distress and immune alterations and when alterations resolved. Our ability to collect immediate previsit data was restricted by the need to not disrupt clinic flow and highly dependent on coordination with providers and clinic staff. We were able to consolidate provider-requested blood tests with our previsit immune markers, eliminating the need for multiple venipunctures. In addition, the clinic allowed us a special private room for self-reported data collection during the 30 minutes prior to medical office visits of consented women, but we had to streamline the amount of collected information to ensure that women were not late for their appointments.
The decision to collect physiologic data immediately before and the morning after a medical office visit, as opposed to longitudinal data that would characterize immune alterations in greater detail, was restricted by the pilot nature of study funding, given the expense of conducting these assays and the expense of participant incentives. Although our institution conducted analyses at a reduced cost, financial considerations dictated both sample size and number of data collection points.
Other limitations include the longstanding patient-provider relationship most women had with their providers and variability in normal values for immune measures, adding challenge to interpretation. Our sample was 100% female, important to note given the suggestion of gender-specific acute stress responses by Breen et al. 52 Future research might focus on the experiences of male survivors and those who have reported more extreme emotional distress and/or markedly unsatisfactory communication interactions to obtain a more clear understanding of the associations between emotional and physiologic alterations in immunity and communication with providers for long-term recurrence-free breast cancer survivors.
n Implications for Practice A T H 1-to-T H 2 shift, indicating a change from cellular innate immunity to adaptive immunity, may predispose women to exacerbations of other illnesses, especially autoimmune diseases, as well as placing them at risk of minor viral and bacterial infections. In this sample, arthritis and hypertension were highly endorsed in the previous month, not unexpected given the relative participant age. The finding that one-third of women had experienced a minor illness in the month prior to a medical oncology surveillance appointment suggests the need for healthcare providers to be vigilant when assessing these women during routine appointments, given the older age of most breast cancer survivors and the prevalence of comorbid conditions.
Healthcare providers have the obligation to identify women who are experiencing emotional distress, knowing that most women experience uncertainty and anxiety prior to a scheduled visit. Providers should consider whether uncertainty or anxiety about the meaning of experienced symptoms is related to concerns about cancer recurrence.
Providers have the opportunity to allay a woman's concern about the meaning of her symptoms with respect to cancer recurrence. In this study, anxiety and uncertainty were reduced overall after the visit, suggesting that women were told by their providers that their breast cancer had not recurred in a believable fashion that may have been enhanced by the longstanding nature of these patient-provider relationships. When the meaning of symptoms is understood, and existing symptoms are not erroneously attributed to breast cancer recurrence, anxiety and uncertainty about cancer recurrence are reduced. 53 Providers could offer answers to questions in between visits via telephone, thus resolving immediate concerns and uncertainty about symptoms. This could be facilitated by nurse-operated, telephone-based ''help lines'' where women could call in without fear of ''bothering the doctor.'' The goal here would be to provide immediate reassurance rather than let women worry for prolonged periods while waiting for their next (often annual) medical surveillance appointment.
While most women were able to achieve their desired decision-making roles, similar to other research one-third of women reported adopting a more passive or active role than initially desired. 6, 38 Providers could engage in a more patientcentered approach to discussions of further testing and/or treatment for symptoms and late-emerging adverse effects of cancer treatment, allowing women to adopt their desired decisionmaking role. 7 The pervasive assumption that a more active patient is desirable may not reflect the role some women want during posttreatment surveillance.
In this study, successful negotiation of decision-making roles did not predict reduction in anxiety and uncertainty or resolution of immunity. This finding may imply that roles were negotiated (successfully or unsuccessfully) in previous visits and as such had no bearing on emotional or physiologic responses to the present visit because the manner of interaction had been previously established with a conscious choice to continue to obtain surveillance from the provider. For women attending their initial oncology surveillance visit, communication processes, such as negotiating decision-making role preference, may be more influential with respect to anxiety and uncertainty during the establishment of the patient-provider relationship. Uncertainty theory suggests that communication between women and their providers has the potential to allay both emotional and physiologic responses to the acute stress of a routine surveillance medical oncology visit, contributing to the overall well-being and ultimate quality of life for long-term breast cancer survivors. 3, 6, 7 Future research could investigate other types of communication processes (eg, how reassurance is provided, the influence of nonverbal communication, facilitative vs directive communication behaviors) to further assess the relationships between communication processes and physical and emotional well-being during cancer survivorship and ongoing surveillance.
In summary, evaluation of responses to real stressors in a naturalistic environment is inherently messy and difficult to interpret. Breast cancer survivors in this study as in others reported uncertainty and anxiety related to ongoing cancer surveillance. Emotional change was associated with change in immunity, although the direction of alteration was inconsistent. Findings illustrate the opportunities, challenges, and complexity of addressing the intersection of survivor-provider communication and emotional and physiologic responses during breast cancer surveillance visits, ultimately facilitating optimal well-being during survivorship.
